primary refractory myeloma

refractory to bortezomib

concomitant anti-cancer therapy (other than bortezomib/dexamethasone and bisphosphonates)

prior treatment with pan-deacetylase inhibitors

clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months prior to randomization)

unresolved diarrhea ≥ Common Terminology Criteria for adverse events grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome and inflammatory bowel disease)

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

What this study is about